U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C16H23N3O4
Molecular Weight 321.3715
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GABEXATE

SMILES

CCOC(=O)C1=CC=C(OC(=O)CCCCCNC(N)=N)C=C1

InChI

InChIKey=YKGYIDJEEQRWQH-UHFFFAOYSA-N
InChI=1S/C16H23N3O4/c1-2-22-15(21)12-7-9-13(10-8-12)23-14(20)6-4-3-5-11-19-16(17)18/h7-10H,2-6,11H2,1H3,(H4,17,18,19)

HIDE SMILES / InChI
Gabexate is a synthetic protease inhibitor, was shown to be effective in treating patients with sepsis-associated disseminated intravascular coagulation in which tumor necrosis factor-alpha (TNF-alpha) plays a critical role. Gabexate mesylate is a drug marketed only in Italy and Japan and it is considered an essential drug in the treatment of acute pancreatitis. Gabexate is marketed under the brand name REMINARON among others in Japan. It relieves inflammatory symptoms in the pancreas by inhibiting various enzymes. It also improves organ disorders and bleeding tendency caused by blood clots in blood vessels by inhibiting blood coagulation. It is usually used to treat acute pancreatitis with deviation of proteolytic enzymes (such as trypsin, kallikrein and plasmin), acute exacerbation of chronic recurrent pancreatitis, acute pancreatitis after surgery and disseminated intravascular coagulation.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
REMINARON

Approved Use

This medicine relieves inflammatory symptoms in the pancreas by inhibiting various enzymes. It also improves organ disorders and bleeding tendency caused by blood clots in blood vessels by inhibiting blood coagulation. It is usually used to treat acute pancreatitis with deviation of proteolytic enzymes (such as trypsin, kallikrein and plasmin), acute exacerbation of chronic recurrent pancreatitis, acute pancreatitis after surgery and disseminated intravascular coagulation.
Primary
REMINARON

Approved Use

This medicine relieves inflammatory symptoms in the pancreas by inhibiting various enzymes. It also improves organ disorders and bleeding tendency caused by blood clots in blood vessels by inhibiting blood coagulation. It is usually used to treat acute pancreatitis with deviation of proteolytic enzymes (such as trypsin, kallikrein and plasmin), acute exacerbation of chronic recurrent pancreatitis, acute pancreatitis after surgery and disseminated intravascular coagulation.
PubMed

PubMed

TitleDatePubMed
Selective inhibition of human mast cell tryptase by gabexate mesylate, an antiproteinase drug.
2001 Feb 1
Patents

Sample Use Guides

Prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: continuous intravenous infusion (600 mg)
Route of Administration: Intravenous
The LPS-induced increase in TNF-a production by human monocytes was significantly inhibited by gabexate mesilate at a concentration of 1.0 x10(-3) M.
Name Type Language
GABEXATE
INN   MI   WHO-DD  
INN  
Official Name English
GABEXATE [JAN]
Common Name English
gabexate [INN]
Common Name English
GABEXATE [MI]
Common Name English
Gabexate [WHO-DD]
Common Name English
ETHYL P-HYDROXYBENZOATE 6-GUANIDINOHEXANOATE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C263
Created by admin on Sat Dec 16 15:51:23 UTC 2023 , Edited by admin on Sat Dec 16 15:51:23 UTC 2023
NCI_THESAURUS C783
Created by admin on Sat Dec 16 15:51:23 UTC 2023 , Edited by admin on Sat Dec 16 15:51:23 UTC 2023
FDA ORPHAN DRUG 764320
Created by admin on Sat Dec 16 15:51:23 UTC 2023 , Edited by admin on Sat Dec 16 15:51:23 UTC 2023
Code System Code Type Description
IUPHAR
7863
Created by admin on Sat Dec 16 15:51:23 UTC 2023 , Edited by admin on Sat Dec 16 15:51:23 UTC 2023
PRIMARY
SMS_ID
100000084507
Created by admin on Sat Dec 16 15:51:23 UTC 2023 , Edited by admin on Sat Dec 16 15:51:23 UTC 2023
PRIMARY
NCI_THESAURUS
C76960
Created by admin on Sat Dec 16 15:51:23 UTC 2023 , Edited by admin on Sat Dec 16 15:51:23 UTC 2023
PRIMARY
CAS
39492-01-8
Created by admin on Sat Dec 16 15:51:23 UTC 2023 , Edited by admin on Sat Dec 16 15:51:23 UTC 2023
PRIMARY
DRUG BANK
DB12831
Created by admin on Sat Dec 16 15:51:23 UTC 2023 , Edited by admin on Sat Dec 16 15:51:23 UTC 2023
PRIMARY
DRUG CENTRAL
3257
Created by admin on Sat Dec 16 15:51:23 UTC 2023 , Edited by admin on Sat Dec 16 15:51:23 UTC 2023
PRIMARY
EVMPD
SUB07858MIG
Created by admin on Sat Dec 16 15:51:23 UTC 2023 , Edited by admin on Sat Dec 16 15:51:23 UTC 2023
PRIMARY
EPA CompTox
DTXSID9048566
Created by admin on Sat Dec 16 15:51:23 UTC 2023 , Edited by admin on Sat Dec 16 15:51:23 UTC 2023
PRIMARY
INN
3988
Created by admin on Sat Dec 16 15:51:23 UTC 2023 , Edited by admin on Sat Dec 16 15:51:23 UTC 2023
PRIMARY
MESH
D016670
Created by admin on Sat Dec 16 15:51:23 UTC 2023 , Edited by admin on Sat Dec 16 15:51:23 UTC 2023
PRIMARY
WIKIPEDIA
GABEXATE
Created by admin on Sat Dec 16 15:51:23 UTC 2023 , Edited by admin on Sat Dec 16 15:51:23 UTC 2023
PRIMARY
FDA UNII
4V7M9137X9
Created by admin on Sat Dec 16 15:51:23 UTC 2023 , Edited by admin on Sat Dec 16 15:51:23 UTC 2023
PRIMARY
MERCK INDEX
m5620
Created by admin on Sat Dec 16 15:51:23 UTC 2023 , Edited by admin on Sat Dec 16 15:51:23 UTC 2023
PRIMARY Merck Index
PUBCHEM
3447
Created by admin on Sat Dec 16 15:51:23 UTC 2023 , Edited by admin on Sat Dec 16 15:51:23 UTC 2023
PRIMARY
ChEMBL
CHEMBL87563
Created by admin on Sat Dec 16 15:51:23 UTC 2023 , Edited by admin on Sat Dec 16 15:51:23 UTC 2023
PRIMARY